From 2012 to 2016, we analyzed a consecutive cohort of DLBCL, NOS for the presence of C-MYC, BCL2, and BCL6 rearrangements and correlated our results with clinical-pathological parameters. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.